Morgan Stanley (NYSE:MS) adjusted its stance on Intellia Therapeutics shares, downgrading the biotechnology company from Overweight to Equalweight. Accompanying this change, the firm also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback